Recommended

GSK appoints new CEO
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Takeda plans 2026 CEO succession

0
SHARES

The biopharmaceutical company’s executive transition follows a multi-year succession process to support its next chapter.

Takeda CEO

Credit: Veroniksha / Shutterstock.com

Christophe Weber is set to retire as Chief Executive Officer (CEO) of Takeda in June 2026 after 12 years. Julie Kim, president of Takeda’s US Business Unit has been appointed as Weber’s successor.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Weber is the company’s current President, CEO and representative director. He joined Takeda as CEO in April 2014. Two months later in June, he transitioned to the role of president and representative director. Weber was subsequently appointed as CEO in April 2015, the company shared.

“Thanks to Christophe’s phenomenal leadership, Takeda has become a global biopharmaceutical powerhouse with a promising late-stage pipeline. I am excited to guide Takeda through the next phase,” stated Kim.

Julie Kim – Takeda’s future CEO

Julie Kim has held the role of president of the US Business Unit and US country head since 2022, taking over from Ramona Sequeira. She has a part of the Takeda Executive Team since 2019.

Kim’s experience in health care spans three decades. Her prior roles span global, regional, country and functional levels. She has worked in a range of therapeutic areas, international market access, general management, marketing and emerging market development, according to Takeda.

“Now is the right time to appoint my successor given our competitive growth outlook, new product launches expected from the second half of 2026 onwards”

“Julie is an outstanding leader who has made significant contributions to the company, notably in leading the US business and the Plasma-Derived Therapies Business Unit previously. She is an experienced, values-based leader who will fully uphold our corporate culture and expand the impact we can have for patients around the world,” remarked Masami Iijima, chair of the Board of Directors meeting and of the Nomination Committee.

“Now is the right time to appoint my successor given our competitive growth outlook, new product launches expected from the second half of 2026 onwards and the anticipated retirement of some external independent directors in the coming years,” explained Weber.

Share via
Share via